Sequential Brands price target raised to $19 from $11 at Canaccord
Canaccord raised its price target on Sequential Brands following its acquisition of Galaxy Brands, citing expectations for increased licensing revenue and the execution of management's growth strategy through M&A. The firm keeps its Buy rating on the shares.
June, 25, 2014 – Today is a landmark day for PPMD and the entire Duchenne community. We are so pleased that at our organization’s 20 year anniversary – after 2 decades of hard work and resolute persistence within the policy, legislative and regulatory arena – we are today able to provide to the US Food and Drug Administration the first-ever patient-initiated guidance to help accelerate development and review of potential therapies for Duchenne muscular dystrophy.
This guidance is a major milestone for the community and truly incorporates the patient voice – the community’s voice – in well-documented and quantifiable ways in pursuit of our common goal – to end Duchenne.
Why Develop a Guidance?
In February 2013, the European Medicines Agency (EMA) developed a guideline document focused on the “clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy.”
We felt that the FDA should have similar guidance and that our well-versed and passionate patient community could come together to provide as much input as possible to inform the document. On December 12, 2013, we convened a national PPMD-FDA Duchenne Policy Forum – with 20 FDA staff members in attendance – where the community made its needs and preferences in drug development known to the Agency. An agreement was reached that we – the Duchenne Community – led by PPMD, would develop the first-ever patient initiated draft guidance on Duchenne.
After an intensive five month long process, overseen by a steering committee, developed by working groups, and reviewed by a community advisory board, today we officially submitted to the FDA the Duchenne muscular dystrophy community’s draft of the Guidance for Industry: Duchenne Muscular Dystrophy: Developing Drugs for Treatment over the Spectrum of Disease, written to help accelerate the development and review of potential therapies for Duchenne.
We had over 80 dedicated expert stakeholders working toge
Roth Capital Boosts Price Target On Sequential Brands To $16
Posted on June 27, 2014 by SmarterAnalyst Staff in Exclusive Area // 0 Comments
In a research note issued today, Roth Capital analyst Dave King raised his price target on Sequential Brands Group, Inc. (SQBG) from $10.00 to $16.00, while maintaining a Buy rating on the stock following SQBG’s agreement to acquire Galaxy Brand Holdings.
King comments: “Sequential Brands entered a definitive agreement to acquire brand licensing competitor Galaxy Brand Holdings for $260M. Although the price looks somewhat expensive, some of the potential benefits include meaningful accretion and the removal of a key competitor for M&A transactions. We continue to like SQBG for its profitable and scalable business model, industryleading management, and fast-growing portfolio of consumer brands.
The analyst continues: “We are increasing our price target from $10 to $16, which now assumes shares should trade at 25x estimated “normalized/targeted” 2016 EPS of $0.65, which is based on the company achieving its $100 million in royalty revenue target with a 70% EBITDA margin. Inherent in this projection is the assumption that future deal multiples will return to management’s targeted range of 5.0x-7.0x. We also believe these royalty revenue and EBITDA targets will get updated as the company approaches this goal through the continued pursuit of 2-3 acquisitions per year”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Dave King currently has an average return of -3.1% and a 36% success rate. He is ranked #2735 out of 3135 analysts.
Keep posting greyzone. I actually agree with much of what you say. I'm still in the camp that believes if you give eteplirsen early enough to these children that you will come to as close of a cure for DMD as possible. As of now, eteplirsen seems to have stopped or significantly slowed down the progression which no drug has ever shown before. Now if you give eteplirsen to a child early enough before any deterioration occurs, who knows what could happen. I am looking forward to the 144 week data. From the parents i have talked to eteplirsen is having an amazing affect. I don't know what the stats will end up showing but we need to compare them to historical averages and see how the drug compares. Even if some of the children declined, how much would they have declined without the drug? What would their 6 mwt be normally if they were never given the drug? It's amazing how companies get valued in the billions and billions for developing a drug that maybe slows down cancer for a few months but Sarepta gets no love when it has a drug that has an unprecedented affect on a deadly disease and now they have the FDA telling them they can file early. And many of those companies aren't even close to approval like we are. Makes no sense to me we are around $30/share given where we are right now. I just don't understand why this company gets absolutely no respect.
Yesterdays strong move higher in markets and this stock went down
Joe Edelman "If the drug works and gets approved, Sarepta has more upside than any other mid-cap stock,"
also, I believe there was a patent filing on exon 53 on behalf of SRPT. it was tweeted and then the tweet was deleted.
Also, there are some who think the 144 week data will be out before the 4th of July. Not sure I agree with that and I don't think that is what is really contributing to the rally today but you never know
Wow. Lots of dilution
n a research note released today, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of Sarepta Therapeutics, Inc. (SRPT), and a price target of $52.00, which represents a potential upside of 102% from where the stock is currently trading.
Pantginis noted, “Sarepta continues to make solid progress with manufacturing and we anticipate patient dosing in the confirmatory study during 3Q 2014, followed by the NDA submission during 4Q 2014. We continue to believe that a 2H-2015, accelerated approval is a high probability event. In our opinion, Sarepta’s PMO-based chemistry has some significant near and long-term advantages over other competing antisense platforms”. The analyst added, “We view the recent weakness in the stock as an opportunity to establish new positions or add to existing positions”
I am hopeful SRPT has finally bottomed a bit. The biggest reason this stock is down is time. Shorts/traders know that the big events (NDA filing) will occur towards the end of the 2nd half so barring any other real surprising news, they have time to knock this stock around. I am using the downward pressure to pick up a few more shares. People get discouraged when they look at the stock price but i look at it as a giant sale.
The issue with RNA's recent financing which makes it different than the one SRPT recently did was not the $150M shelf but the secondary offering for insiders to sell 18.9M shares (worth ~$240M at the current market price): That shows very little confidence by ownership. That is the reason RNA got socked. Everyone knew they would raise by the secondary offering was a big surprise (negative imo)
Well, that doesn't help either, along with GSK bailing on the entire program but i think the immediate issue was the secondary offering.
Should be going higher
Etep seems to be working!
He's looking fantastic!!
and be celebrated. However Eteplirsen is showing the ability to significantly slow down the disease (imagine if it was administered before these children suffered any decline), something no other drug has ever been able to do and it appears completely safe, it's still criticized. amazing